Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Intravenous Iron on Celiac Disease Remission
2019-003125-21Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric carboxymaltose in celiac disease (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Total villous recovery (total remission) on last duodenal biopsies. Started Jan 2020; status: active.
02
Drugs
ferric carboxymaltose
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2019-003125-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003125-21.